Key facts
- Notable investors include Boost VC, BlueYard Capital, MassBio, LabCentral, SciFounders — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for HarborSite
- ·The full record, as it builds
Funding rounds
No funding rounds for HarborSite are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HarborSite
Developer of a genome engineering platform designed for safe and efficient gene insertion for the treatment of genetic and age-associated diseases. The company applies large-scale computation genomics, high-throughput experimental screening, and enzyme optimization workflows to identify andhigh-throughput experimental screening, and enzyme optimization workflows to identify and engineer potent, safe integration tools, enabling biotechnology companies and gene therapy developers with targeted genomic editing capabilities that improve therapeutic efficacy, safety, and scalability.
- Sector
- Healthcare
- HQ
- NC
- Founded
- 2023
- Employees
- 4
- Website
- harborsite.com/
- Ownership
- Privately Held (backing)
HarborSite doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HarborSite shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HarborSite in its N-PORT filings yet. We sweep new filings monthly.